Close

Have A Question?


Connect with Camargo today.

Contact Us
Blog & Resources Camargo Blog Regulatory

The Camargo Blog

Get insight and information from our team of experts to improve your pharmaceutical development and commercialization strategy.


October 13th, 2017

Not a Generic? Must Be a 505(b)(2)?

October 11th, 2017

Drug or Device?—FDA Provides More Clarity—Or Does It?

October 4th, 2017

Product Selection: Which Product to Develop?

September 13th, 2017

Navigating Clinical Holds

September 6th, 2017

De-Risking Drug Development

August 30th, 2017

Optimizing Your Global Drug Development Program: Strategy for Regional Variations of the 505(b)(2) Pathway

August 23rd, 2017

The Target Product Profile: Your Strategy to Reduce Development and Review Time

August 17th, 2017

Stability Requirements in the 505(b)(2) Space: Why, What, When, How

August 2nd, 2017

Deuterization: Is it Enough to Get 5- or 7-Year Exclusivity for a 505(b)(2) Product?

July 26th, 2017

Recent Developments for Abuse-Deterrent Opioids: FDA and Payers Influence Societal and Market Impact

July 12th, 2017

Pre-IND Meetings: The Increasing Frequency of Written Responses Only, and Which FDA Divisions Use Them the Most

June 14th, 2017

A Green Card Is No Longer a “Green Light”—Changes to FDA Security Policy

May 24th, 2017

What Went Wrong? Important Outcomes of a Successful Pre-IND Meeting

May 10th, 2017

The Value of a Strategic Assessment: Aligning for Success from the Start

April 26th, 2017

Abuse-Deterrent Opioids—The Insider’s Guide to Innovation and Exclusivity in a Changing Regulatory Landscape

April 5th, 2017

Shortening the Review Clock: the Latest on Priority Review Vouchers

March 8th, 2017

Pre-IND Meetings: How to Achieve Success for 505(b)(2)

February 1st, 2017

Real-World Evidence: Can It Really Be Used for Drug Approvals?

January 18th, 2017

Unforced Errors: FDA Refusal to File or Receive Letters

December 20th, 2016

Improving NDA Approval Odds for New Dosage Forms of Approved Products

December 14th, 2016

A New Indication for an Old Drug. What Could Go Wrong?

December 5th, 2016

Dramatically Decrease Drug Development Costs Through Literature-Only 505(b)(2) NDA Submissions

November 16th, 2016

PRO-CTCAE: Improving Oncology Drug Development

November 3rd, 2016

Expedited Approval of FDA-Approved Drugs in Australia

Page 2 of 10


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights